Glycemic Variability and Time in Range During Self-titration of Once Daily Insulin Glargine 300 U/ml Versus Neutral Protamine Hagedorn Insulin in Insulin-naïve Chinese Type 2 Diabetes Patients
| العنوان: | Glycemic Variability and Time in Range During Self-titration of Once Daily Insulin Glargine 300 U/ml Versus Neutral Protamine Hagedorn Insulin in Insulin-naïve Chinese Type 2 Diabetes Patients |
|---|---|
| المؤلفون: | Risa Ozaki, Elaine Chow, James Ling, Ronald C.W. Ma, Kit-Man Loo, Aimin Yang, Theresa Yeung, Andrea O.Y. Luk, Emily Poon, Alice P.S. Kong, Juliana C.N. Chan |
| المصدر: | Diabetes Therapy |
| بيانات النشر: | Springer Science and Business Media LLC, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, 030209 endocrinology & metabolism, NPH insulin, Type 2 diabetes, 030204 cardiovascular system & hematology, Hypoglycemia, Gastroenterology, Bedtime, 03 medical and health sciences, 0302 clinical medicine, Diabetes mellitus, Internal medicine, Internal Medicine, medicine, Continuous glucose monitoring, Original Research, Glycemic, Insulin analogues, business.industry, Insulin glargine, Insulin, nutritional and metabolic diseases, Glucose variability, medicine.disease, business, medicine.drug |
| الوصف: | Introduction To compare glycemic variability (GV) and time in range (TIR) in Chinese patients with type 2 diabetes (T2D) initiated on once-daily bedtime insulin glargine 300U/ml (Gla-300) versus neutral protamine Hagedorn (NPH) insulin using continuous glucose monitoring (CGM). Methods This was a 24-week, open-label exploratory study with 1:1 randomization comparing patient-adjusted titration of Gla-300 (n = 23) versus NPH (n = 23) at bedtime in insulin-naïve T2D patients on maximum oral glucose-lowering drugs. The starting dose was 0.2 U/kg/day and with self-titration of one unit per week to achieve a target fasting glucose of 4.4–6 mmol/l, without hypoglycemia. Participants had masked CGM at baseline, weeks 11 and 24. The primary outcome was between-treatment differences in CGM glucose standard deviation (SD) at week 24. Results HbA1c at week 24 were similar, with 21% of Gla-300 versus 4% of NPH-treated patients achieving HbA1c |
| تدمد: | 1869-6961 1869-6953 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e29dc8218007b703540b0d7f6e3eb284Test https://doi.org/10.1007/s13300-021-01046-6Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....e29dc8218007b703540b0d7f6e3eb284 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 18696961 18696953 |
|---|